Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies

• Published in: Scientific reports Vol. 12; no. 1; pp. 12920 - 12
• Main Authors: Kutkat, Omnia, Moatasim, Yassmin, Al‐Karmalawy, Ahmed A., Abulkhair, Hamada S., Gomaa, Mokhtar R., El-Taweel, Ahmed N., Abo Shama, Noura M., GabAllah, Mohamed, Mahmoud, Dina B., Kayali, Ghazi, Ali, Mohamed A., Kandeil, Ahmed, Mostafa, Ahmed
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 28.07.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154; 639/638; 692/699; Amitriptyline; Antidepressants; Antiviral activity; Antiviral agents; Antiviral drugs; Clinical trials; Coronaviruses; COVID-19; Eating disorders; Headache; Humanities and Social Sciences; Imipramine; Mental depression; Middle East respiratory syndrome; Migraine; multidisciplinary; Neuralgia; Pandemics; Paroxetine; Patients; Prophylaxis; Science; Science (multidisciplinary); Sertraline; Severe acute respiratory syndrome coronavirus 2

During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and asymptomatic quarantined COVID-19 patients. Despite that many of the FDA-approved drugs have been showed anti-SARS-CoV-2 activity in vitro and remarkable efficac...